The French Competition Authority hands down a non-suit decision regarding alleged abuse of dominant position in the parallel trade of medicines (Pharma-Lab / GlaxoSmithKline)

Parallel trade in medicines: Pharmaceutical laboratories do not abuse their dominant position when they restrict or refuse deliveries of medicines to exporters, who seek to purchase products in France at an administered price,in order to then sell them on in another country at a higher price.* Following a referral by several exporting companies regarding practices implemented by 21 pharmaceutical laboratories [1], the Conseil de la concurrence has handed down a non-suit decision, on the grounds that the behaviour concerned by the complaint could not be qualified as abuse of a dominant position under French and EC competition law. Parallel trade in medicines in Europe "Parallel trade in pharmaceuticals" is based on the existence of different prices for

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.